4-(2-甲基-3-吲哚基)哌啶 | 65347-61-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-(2-甲基-3-吲哚基)哌啶
• 中文别名: 4-(2-甲基-3-吲哚)哌啶
• 英文名称: 2-methyl-3-(piperidin-4-yl)-1H-indole
• 英文别名: 2-methyl-3-piperidin-4-yl-1H-indole
• CAS: 65347-61-7
• 化学式: C₁₄H₁₈N₂
• mdl: MFCD03426298
• 分子量: 214.31
• InChiKey: AQFCUPJDFCEYNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

文献信息

• TRICYCLIC TRIAZOLE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0536419A1

  公开（公告）日：1993-04-14

  A novel tricyclic triazole derivative represented by general formula (I) and a pharmacologically acceptable salt thereof, useful as an antiinflammatory, antiallergic and anti-PAF drug, and a process for the production thereof. In formula (I), R¹ represents hydrogen, lower alkyl or C₃ to C₅ cycloalkyl; R² and R³ represent each hydrogen, lower alkyl, lower alkoxy or halogen; W represents C = O or CR⁴R⁵ wherein R⁴ and R⁵ represent each hydrogen or lower alkyl; A represents C₁ to C₅ saturated or unsaturated alkylene which may contain a heteroatom; 1 represents 0 to 2; n represents 1 to 3; symbol --¯ represents a single or double bond; Y represents N or C; and Z represents C(B)Ar¹Ar² (wherein B represents hydrogen, hydroxy or methoxy, and Ar¹ and Ar² represent each hydrogen or (un)substituted aryl), CAr¹Ar² (wherein Ar¹ and Ar² are each as defined above), O-CHAr¹Ar² (wherein Ar¹ and Ar² are each as defined above) or a condensed aromatic ring.

  一种由通式(I)代表的新型三环三唑衍生物及其药理学上可接受的盐，可用作抗炎、抗过敏和抗PAF药物，及其生产工艺。在式 (I) 中，R¹ 代表氢、低级烷基或 C₃ 至 C₅ 环烷基；R² 和 R³ 分别代表氢、低级烷基、低级烷氧基或卤素；W 代表 C = O 或 CR⁴R⁵，其中 R⁴ 和 R⁵ 各自代表氢或低级烷基；A 代表 C₁ 至 C₅ 饱和或不饱和亚烷基，其中可包含一个杂原子；1 代表 0 至 2；n 代表 1 至 3；符号--¯代表单键或双键；Y代表N或C；Z代表C(B)Ar¹Ar²（其中B代表氢、羟基或甲氧基，Ar¹和Ar²分别代表氢或（未）取代的芳基）、CAr¹Ar²（其中Ar¹和Ar²分别如上定义）、O-CHAr¹Ar²（其中Ar¹和Ar²分别如上定义）或缩合芳环。
• Indole derivatives useful as histamine H3 antagonists
  申请人：SCHERING CORPORATION

  公开号：EP1777223A1

  公开（公告）日：2007-04-25

  Disclosed are novel compounds of the formula I wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are the uses of the compounds of formula I for treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion). Also disclosed are uses of the compounds of formula I in combination with a H1 receptor antagonist for treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion).

  公开了式 I 的新型化合物，其中 M1 是 CH 或 N，M2 是 C(R3) 或 N；R1 是任选取代的吲哚基或其氮杂衍生物；R2 是任选取代的芳基或杂芳基；其余变量如说明书中所定义。还公开了包含式 I 化合物的药物组合物。还公开了式 I 化合物用于治疗各种疾病或病症的用途，例如过敏、过敏引起的气道反应和鼻塞（如鼻塞）。还公开了式 I 化合物与 H1 受体拮抗剂结合用于治疗各种疾病或病症的用途，例如过敏、过敏引起的气道反应和充血（如鼻塞）。
• TRICYCLIC TRIAZOLE DERIVATIVES, PRODUCTION AND USE THEREOF
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0536419B1

  公开（公告）日：1999-10-13
• Pharmaceutical Compound
  申请人：IOMET PHARMA LTD

  公开号：US20160367564A1

  公开（公告）日：2016-12-22

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 2 , X 4 , X 10 , and X 11 may be the same or different and each is independently selected from C and N; X 1 , X 3 , X 5 , X 6 , X 7 , X 8 , and X 9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X 4 with the carbon atoms either side of X 2 are single bonds, and are only present when X 2 is absent, X 3 is absent and X 4 is C, and when these bonds are present the ring carbons on each side of X 2 are not directly bonded to each other; each R 1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 1 groups present is such that the valency of X 1 is maintained; each R 12 , R 13 , R 13′ , R 14 , R 15 and R 15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R 16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 16 groups present is such that the valency of X 2 is maintained; each R 17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R 17 groups present is such that the valency of X 3 is maintained; each R 2 , R 3 , R 4 , and R 5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 6 , X 7 , X 8 , and X 9 are maintained; each R 7 , R 8 and R 9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 10 , X 11 , and X 5 are maintained; and R 6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C 1 -C 6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.
• US4100291A
  申请人：——

  公开号：US4100291A

  公开（公告）日：1978-07-11